Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa
Open Access
- 17 May 2007
- journal article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 7 (1), 41-8
- https://doi.org/10.1186/1471-2334-7-41
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of MalawiAIDS, 2006
- Determinants of Mortality and Nondeath Losses from an Antiretroviral Treatment Service in South Africa: Implications for Program EvaluationClinical Infectious Diseases, 2006
- Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in ZambiaJAMA, 2006
- Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis controlAIDS, 2006
- Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort studyAIDS, 2006
- CURRENT ISSUES AND FORTHCOMING EVENTSJournal of Advanced Nursing, 2006
- How can earlier entry of patients into antiretroviral programs in low-income countries be promoted?Clinical Infectious Diseases, 2006
- Release of urokinase plasminogen activator receptor during urosepsis and endotoxemiaKidney International, 2001
- Prognostic Value of Single Measurements of Beta-2-microglobulin, Immunoglobulin A in HIV Disease After Controlling for CD4 Lymphocyte Counts and Plasma HIV RNA LevelsScandinavian Journal of Infectious Diseases, 2000
- The area above the ordinal dominance graph and the area below the receiver operating characteristic graphJournal of Mathematical Psychology, 1975